EQUASHIELD®, a global leader in healthcare innovation, has officially announced the launch of CellSHIELD®, which happens to be a groundbreaking device, geared towards transforming cell and gene therapy manufacturing.
According to certain reports, the stated new disposable system arrives bearing an ability to rethink industry standards, all for the purpose of achieving unparalleled safety, efficiency, and scalability across today’s life sciences industry.
“We see such low volume loss with CellSHIELD®, that once we switch people over, there really is no comparison. Little to no volume loss, less than 0.1%,” said a representative from a leading cell therapy CDMO.
More on the same would reveal how CellSHIELD® is capable of reducing cost, improving efficiency, and supporting product safety. You see, leveraging a fully closed design, such a mechanism should really go the distance to achieve sterility and biocontainment, empowering biopharma companies and CDMOs to scale operations safely and efficiently.
Not just that, it also simplifies processes and cuts down on training requirements to accelerate onboarding, and at the same time, enhance productivity.
Markedly enough, the given device’s underlying infrastructure makes it a suitable component for common applications, such as in-process testing and cell culture sampling, sterile fluid transfer between vessels, and air removal to eliminate bubbles,
“The launch of CellSHIELD® underscores our commitment to advancing medical treatments through cutting-edge technology. This device not only enhances safety and efficiency, but also supports the scalability required to meet the growing demand for cell and gene therapies,” said Jason Dutcher, Director of Strategic Accounts at EQUASHIELD.
Talk about the whole value proposition on a slightly deeper level, we begin from the promise of patient safety and quality. This translates to how, through the already-stated sterility and biocontainment across the manufacturing process, CellSHIELD® is also able to maintain the highest standards of patient safety and product quality.
Next up, the solution focuses on generating a rather simpler and efficient mechanism, something which stems from CellSHIELD®’s bid to ensure simple, repeatable processes that reduce the risk of errors and improve operational efficiency.
Another detail worth is rooted in the requirement for minimal training. EQUASHIELD®’s latest is basically designed to minimize the need for extensive training, thus enabling faster onboarding and productivity.
Beyond that, there is the availability of proven CSTD expertise. Thanks to EQUASHIELD®’s expertise in Closed System Transfer Devices (CSTD), CellSHIELD® can seamlessly generate proven trusted safety and containment principles for cell and gene therapy manufacturing.
“CellSHIELD® represents a significant leap forward in cell and gene therapy manufacturing,” said Matt Stuckert, General Manager of EQUASHIELD®. “Our mission has always been to innovate and provide solutions that address the most pressing challenges in healthcare. With CellSHIELD®, we are empowering manufacturers to deliver life-saving therapies more efficiently and safer than ever before.”
